ViRob - Microbot Medical
technology-template-default,single,single-technology,postid-33,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-3.4,wpb-js-composer js-comp-ver-4.12.1,vc_responsive




ViRob Platform



The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.  It’s miniature dimensions allowing it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system.  Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time.


Self-Cleaning Shunt (SCS)


Market Facts

Hydrocephalus, also known as “water in the brain,” is a medical condition, presented mostly in babies, in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. The same condition, known as Normal Pressure Hydrocephalus (NPH), presented mostly in the elderly population, causing thinking and reasoning problems, difficulty walking, etc.

  • Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone 1,2
  • Over 1,000,000 people in the United States currently live with hydrocephalus 1
  • It is estimated that more than 700,000 Americans have NPH, but less than 20% receive an appropriate diagnosis 1
  • The problem is often misdiagnosed as Dementia, Alzheimer’s, or Parkinson’s 2
  • NPH can cause dementia, difficulty in walking and, urinary incontinence 2
  • Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated operations are often required 3
  • Ventricular catheter blockage is by far the most frequent events 4

Our Solution

The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid (CSF) shunt system.  Microbot’s ventricular catheter can connect to existing valves currently on the market and maintain CSF flow through the ventricular catheter. It is expected that the SCS device will replace all ventricular catheters, while drastically reducing, and potentially eliminating, shunts occlusions.



  1. NIH, National Institute of Neurological Disorders and Stroke.
  2. National Hydrocephalus Foundation.
  3. Hydrocephalus Association.
  4. World Federation of Neurological Societies.